MONOACYLGLYCEROL LIPASE INHIBITOR MJN110 REDUCES NEURONAL HYPEREXCITABILITY, RESTORES DENDRITIC ARBORIZATION COMPLEXITY, AND REGULATES REWARD-RELATED BEHAVIOR IN PRESENCE OF HIV-1 TAT

Alexis Fraser League

A thesis submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Master of Arts in the Department of Psychology & Neuroscience in the College of Arts and Sciences (Behavioral and Integrative Neuroscience).

Chapel Hill
2021

Approved by:
Sylvia Fitting
Regina Carelli
Todd Thiele
ABSTRACT

Alexis Fraser League: Monoacylglycerol Lipase Inhibitor MJN110 Reduces Neuronal Hyperexcitability, Restores Dendritic Arborization Complexity, and Regulates Reward-Related Behavior in Presence of HIV-1 Tat
(Under the direction of Sylvia Fitting)

While current therapeutic strategies for people living with human immunodeficiency virus type 1 (HIV-1) suppress virus replication peripherally, viral proteins including transactivator of transcription (Tat) contribute to chronic inflammatory conditions even alongside antiretroviral treatment. As demand grows for strategies to reduce resulting inflammation associated neurocognitive disorders, this study probed the therapeutic potential of inhibiting monoacylglycerol lipase (MAGL) to upregulate 2-arachidonoylglycerol (2-AG) and regulate inhibitory neuronal activity.

In vitro, MAGL inhibitor MJN110 reduced hyperexcitability and increased dendritic branching complexity in Tat-treated frontal cortex neurons. In vivo, MJN110 administration increased 2-AG in the prefrontal cortex (PFC) and striatum across groups, and restored PFC N-arachidonylethanolamine levels in Tat(+) subjects. While Tat increased reward-related learning in a novel cognitive flexibility assay, MJN110 altered reversal learning specifically in Tat(+) mice to rates indistinguishable from Tat(-) controls. Collectively, results suggest MAGL inhibition is neuroprotective against neuronal hyperexcitability, dendritic arborization simplification, and neurocognitive alterations driven by Tat.
TABLE OF CONTENTS

List of Tables ........................................................................................................................................ vi
List of Figures ........................................................................................................................................ vii
List of Abbreviations ........................................................................................................................... viii
Introduction .......................................................................................................................................... 1
Materials and Methods .......................................................................................................................... 4
    Primary Neuron Cultures .................................................................................................................. 4
    Treatments in vitro .......................................................................................................................... 5
Live-Cell Fluorescence Imaging ........................................................................................................... 5
Immunocytochemistry .......................................................................................................................... 6
Animals .............................................................................................................................................. 6
Treatments in vivo ................................................................................................................................ 7
Odor Discrimination Flexibility Task ................................................................................................. 7
Ultraperformance Liquid Chromatography/Tandem Mass Spectrometry (UPLC-MS/MS) ...................... 10
Data Analysis ..................................................................................................................................... 11
Results ............................................................................................................................................. 13
Live-Cell Fluorescence Imaging .......................................................................................................... 13
    Glutamate-induced Intracellular [Ca^{2+}] Increase Was Dysregulated by Tat Pretreatment and Downregulated by MJN110 in a Concentration-Dependent Manner ....................................................... 13
    Tat-induced Dysregulation of [Ca^{2+}] Increase Was Mitigated by Pretreatment with MJN110 in a Time- and Concentration-Dependent Manner ........................................................................................... 15
Immunocytochemistry ........................................................................................................... 17

Dendritic Branching Complexity was Increased in Tat-Exposed Frontal Cortex
Neurons Treated with MJN110 .......................................................................................... 17

Odor Discrimination Flexibility Task ............................................................................... 18

Rate of Shaping Acquisition Was Faster in Tat(+) Subjects ........................................... 18

Faster Reversal Acquisition in Tat(+) Subjects Was Slowed to Rates Comparable to
Tat(−) Controls with MJN110 Treatment ........................................................................ 18

Neither Genotype Nor MJN110 Treatment Significantly Affected Within-Trial
Response Latency .......................................................................................................... 19

Tat Expression Did Not Influence Reinforcer Consumption Volume ............................. 20

Tat Expression Did Not Influence Olfactory Sensitivity ............................................... 20

UPLC-MS/MS ................................................................................................................... 20

2-AG and AEA Were Differentially Expressed Across Examined Brain Regions
Between Tat and MJN110 Conditions ............................................................................. 20

PFC AA and Striatal AEA Levels Positively Correlated with Within-Trial
Response Latency in Tat(+) and MJN110-Treated Subjects, Respectively ..................... 21

Discussion ....................................................................................................................... 23

Conclusion ......................................................................................................................... 27

References ......................................................................................................................... 28
LIST OF TABLES

Table 1 – *In vitro* calcium imaging of Tat- and MJN110-treated frontal cortex neurons ..........17
Table 2 – Assessment of Tat and MJN110 treatment *in vitro* at different time points..............19
LIST OF FIGURES

Figure 1 – *In vitro* calcium imaging of Tat- and MJN110-treated frontal cortex neurons ..........14

Figure 2 – Assessment of Tat and MJN110 treatment *in vitro* at different time points ..........16

Figure 3 – *In vivo* behavioral flexibility task ................................................................................18

Figure 4 – Behavioral flexibility task supplemental measures .....................................................19

Figure 5 – *Ex vivo* quantification of cannabinoid tone in brain tissue ........................................21
**LIST OF ABBREVIATIONS**

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| 2-AG         | 2-arachidonoylglycerol                           |
| 2-PE         | 2-phenylethanol                                  |
| AA           | Arachidonic acid                                 |
| AEA          | N-arachidonylethanolamine                        |
| ANOVA        | Analysis of variance                             |
| cART         | Combination antiretroviral therapy               |
| CB₁R         | Cannabinoid receptor type-1                      |
| CB₂R         | Cannabinoid receptor type-2                      |
| CNS          | Central nervous system                           |
| COX          | Cyclooxygenase                                   |
| DOX          | Doxycycline                                      |
| DAT          | Dopamine transporter                             |
| E17          | Embryonic day 17                                 |
| GFAP         | Glial fibrillary acidic protein                  |
| HAND         | HIV-associated neurocognitive disorders          |
| HIV-1        | Human immunodeficiency virus type-1              |
| ISTD         | Internal standard                                |
| MAGL         | Monoacylglycerol lipase                          |
| MRM          | Multiple reaction monitoring                     |
| NMDA         | N-methyl-D-aspartate                             |
| ODF          | Odor discrimination flexibility                  |
| PFC          | Prefrontal cortex                                |
| Abbreviation | Description                                    |
|--------------|-----------------------------------------------|
| PWH          | People with latent HIV-1                      |
| Tat          | Transactivator of transcription               |
| UPLC-MS/MS   | Ultraperformance liquid chromatography/tandem mass spectrometry |
INTRODUCTION

With the advent of combination antiretroviral therapy (cART), mortality rates among human immunodeficiency virus type-1 (HIV-1)-infected individuals have decreased by more than 50% (1). The consequent growth in the population of people with latent HIV-1 (PWH) has introduced a new demand for supplemental treatments, as cART itself is neurotoxic with prolonged exposure (2, 3) and leads to greater susceptibility to issues driven by synaptic dysfunction including HIV-associated neurocognitive disorders [HAND, (4)], which occurs in up to 50% of infected individuals (5). Further, cART is largely unable to deplete expression of residual HIV-1 proteins in the tissues of the central nervous system [CNS; (6–9)]. One such viral protein, transactivator of transcription (Tat) enters the host genome early after infection (10), and has been shown to induce synaptodendritic injury and cognitive deficits in murine models of HIV-1 (11–14) by altering the cellular environment through proinflammatory processes which contribute significantly to the pathogenesis of HAND (7, 15, 16).

Previous work has demonstrated in vitro Tat excitotoxicity (17–19) which is downregulated in frontal cortex primary neuron cultures with direct application of endogenous ligands N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) via cannabinoid receptors type-1 [CB1R; (20)]. Blocking enzymatic degradation of 2-AG and/or AEA likely has greater translational value, as activity of endogenous ligands and associated downstream products provides an extended therapeutic window due to longer half-life and greater conferred selectivity at target receptors relative to many currently available phytocannabinoid-based treatments (21–23). Additionally, therapeutic enhancement of cannabinoid signaling by enzyme
inhibitors appears to be localized to sites of injury in contrast to direct agonists, which more widely affect cannabinoid signaling across the brain and are more likely to drive off-target effects (24–27).

The endocannabinoid system is a promising avenue for development of therapeutic strategies in disease, as existing literature shows anti-inflammatory and neuro-regulatory properties of agonists at CB1R (28–30) and cannabinoid receptors type-2 [CB2R; (31, 32)]. Potential neuroprotective effects of the endocannabinoid system in the context of neuroHIV have been reviewed previously (33, 34). Activation of CB1R and CB2R may downregulate the proinflammatory cytokine levels associated with synaptodendritic injury (35, 36), behavioral disturbances observed in PWH and HIV-1 transgenic rats (36, 37), and peripheral neuropathy (38–40). Nevertheless, therapeutic use of the CB1R agonists are limited due to associated pervasive psychoactive side effects including sensorimotor, affective, and cognitive disturbances (41). Thus, research efforts have focused on development of drugs targeting components of the endogenous cannabinoid system, including enzymes regulating the biosynthesis and degradation of the endogenous cannabinoids AEA and 2-AG to enhance tonic endocannabinoid activity (42–44).

Of particular interest is the effect of monoacylglycerol lipase (MAGL), which contributes to about 85% of total 2-AG hydrolysis in the CNS (45, 46). In addition to promoting activity at CB1R, inhibition of MAGL has recently been shown to downregulate inflammation in central (47) and peripheral (48) nervous system models by reducing breakdown of endogenous ligands into inflammatory metabolites such as arachidonic acid [AA; (49)] and downstream products like prostaglandins (47, 50). As increased prostaglandin activity drives inflammatory responses, reduction of AA production may reduce neuroinflammation caused by CNS insult. Indeed,
MAGL inhibitor MJN110 has demonstrated neuroprotective effects in models of neuropsychiatric and neurodegenerative diseases (51) and ischemic stroke (52).

The aims for this project were 4-fold: first, to characterize neuroprotective effects of MJN110 treatment against Tat-associated excitotoxicity in frontal cortex neuron cultures via live calcium imaging; second, to assess Tat- and MJN110-induced alterations to neuronal morphology via immunocytochemistry in vitro; third, to assess the effects of Tat and MJN110 treatment in vivo using a HIV-1 Tat transgenic mouse model (13, 53) of behavioral flexibility as an indicator of MJN110 efficacy in restoring prefrontal cortex function (54–56); and fourth, to characterize brain region-specific alterations to endocannabinoid-related protein expression as a function of Tat and MJN110 treatment via ultrahigh performance liquid chromatography tandem mass spectrometry.
MATERIALS AND METHODS

Experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All procedures were approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.

PRIMARY NEURON CULTURES

Primary neuron cultures were derived from embryonic day 17 (E17) C57BL/6J mouse (Charles River, Raleigh, NC) frontal cortex and incubated as previously described (32). Briefly, brains were collected and frontal cortex tissue was dissected and minced. Neurons were isolated with 30-min incubation (37°C) in neurobasal medium (ThermoFisher Scientific, #21103049, USA) with 2.5 mg/mL trypsin, 0.015 mg/mL DNAse, 2% B27 (50X; ThermoFisher Scientific, #17504044, USA), 0.5 mM L-glutamine (ThermoFisher Scientific, #25030081, USA), 25 mM glutamate (Sigma-Aldrich, #604968, USA), and 1% penicillin-streptomycin (ThermoFisher Scientific, #15140122, USA). Tissue was triturated and filtered twice through 70 μm pore nylon mesh before dissociated cells were plated on poly-L-lysine-coated (Sigma-Aldrich, #P2636) 35 mm glass-bottom dishes (MatTek, #P35G-0-10-C, USA; 1 * 10^5 cells per dish) or cover slips (Fisherbrand 22 mm microscope cover slips, Cat No. 12-547, USA; 2 * 10^5 cells per slip) for calcium imaging or immunocytochemistry, respectively. Neurons were maintained in a humidified incubator with 5% CO₂ at 37 °C (Eppendorf, Hauppauge, NY) in neurobasal medium supplemented with 25 μM glutamate, 2% B27, 0.5 mM L-glutamine, and 1% penicillin-streptomycin. Supplemented medium was 50% exchanged every 48 h. On day in vitro 10, cells were prepared for imaging.
TREATMENTS IN VITRO

Primary frontal cortex neuron cultures were treated with HIV-1 Tat1–86 (50–100 nM; ImmunoDx, IIIB, #1002, USA), glutamate (0.1–10 μM; Sigma-Aldrich, #604968, USA), and/or MJN110 (0.5–1 μM; 50), which were diluted in Hanks Balanced Salt Solution (HBSS; ThermoFisher Scientific, #14025092, USA) supplemented with 10 mM HEPES (ThermoFisher Scientific, #15630080, USA). Tat1–86 concentrations in the 50–100 nM range were chosen for the present study as they recapitulate cellular deficits observed in PWH (57–60). For experiments using glutamate to induce excitation, a subthreshold concentration of Tat1–86 [50 nM; i.e., concentration insufficient to elicit excitatory response when bath-applied to neurons; established by (32) was used to drive neurons into a disease state prior application of glutamate during imaging. Concentrations of glutamate and MJN110 were chosen based on preliminary experiments (Supplementary Figure 1) and previous studies (61) which assessed activity elicited in vitro by this neurotransmitter and drug, respectively.

LIVE-CELL FLUORESCENCE IMAGING

Neurons were incubated for 30 min in fluorescent intracellular calcium indicator fura-2 AM (2 μL/mL; ThermoFisher Scientific, #F1221, USA) diluted in HBSS (with Ca²⁺, ThermoFisher Scientific, #14025076, USA) supplemented with HEPES (10 mM; ThermoFisher Scientific, #15630080, USA) according to manufacturer instructions. Half of the neurons were then exposed to 50 nM Tat (Figure 1) and/or MJN110 (500 nM or 1 μM; Figure 2) for an additional 1 h or 30 min prior to imaging (Figures 1, 2, respectively). Relative fluorescence ratio images were recorded for 30 min with a computer-controlled stage encoder with environmental control (37 °C, 95% humidity, 5% CO₂) using a Zeiss Axio Observer Z.1 inverted microscope (Zeiss, Thornwood, NY, USA) with a 20x objective at 340/380 nm and 510 nm
excitation and emission wavelengths, respectively. Following 1 min baseline imaging, 10 μM glutamate (Figure 1) or 100 nM Tat (Figure 2) was bath-applied to cultures. Excitation patterns were assessed for the remaining 29 min. Fifteen neurons were randomly selected from each culture and somas from each were tagged as regions of interest. Relative fluorescence ratios were used to quantify fluctuations in intracellular calcium ion ([Ca^{2+}]_i) activity across the experimental timeframe (62). At least three independent experiments were run for each treatment group.

**IMMUNOCYTOCHEMISTRY**

Neurons were fixed for 10 min with 4% paraformaldehyde in phosphate-buffered saline (ThermoFisher Scientific, #J61899-AP, USA) and stained as previously described (32). In brief, neurons were immunolabeled using primary antibodies against MAP2ab (Millipore, MAB378, USA; 1:500) with secondary antibodies conjugated to goat-anti-mouse Alexa 488 (ThermoFisher Scientific, #O-6380, USA; 1:1,000) diluted in PBS (ThermoFisher Scientific, #20012043). Nuclei of cells were stained using Hoechst 33342 (3 min; ThermoFisher Scientific, #H3570, USA) and coverslips were mounted using Prolong Gold (ThermoFisher Scientific, #P36930, USA). Z-stack images were obtained using ZEN 2010 Blue Edition software (Zeiss, Thornwood, NY, USA) with a Zeiss LSM 700 laser scanning confocal microscope using a 63x immersion objective (Zeiss, Thornwood, NY, USA). Dendritic branching complexity (e.g., maximum process length and distance from soma with maximal branching) and soma area were assessed with orthogonal projections from Z-stack images using the Sholl analysis tool within ImageJ software [Version 2.1.0; (63)].

**ANIMALS**

Brain-restricted, doxycycline-inducible HIV-1 IIIB Tat1–86 transgenic mice were developed on a hybrid C57BL/6J background as previously described (53, 64) using a
tetracycline “on” system. Mice expressing Tat under the tetracycline-responsive element were crossed with mice expressing glial fibrillary acidic protein (GFAP) promoter-driven reverse tetracycline transactivator. Expression was induced with 6 mg/g doxycycline (DOX) administration through chow diet (product TD.09282; Envigo, Indianapolis, IN, USA). Genotyping by PCR was performed at 4 weeks of age to determine which mice were Tat(+) (i.e., expressing both GFAP-rTA and TRE-tat genes) and which were Tat(−) (i.e., expressing only the GFAP-rTATA gene).

Twenty-four female transgenic mice [12 Tat(+)] 3–4 months of age were held on *ad libitum* DOX chow diet (6,000 ppm, TD.09282, Envigo, NJ, USA) for 3 months prior to and throughout behavioral testing to induce and maintain Tat expression. All tests took place in the colony room during the dark phase of the 12-h light cycle.

**TREATMENTS IN VIVO**

For behavioral experiments, 1 mg/kg MJN110 (61) dissolved in saline-based vehicle [1:1:18; ethanol, Kolliphor (Sigma-Aldrich, #C5135, USA), and 0.9% NaCl saline, respectively; (25)] or vehicle alone was injected subcutaneously (10 μL/g body mass) for 5 days preceding, then throughout reversal trials (Figure 3). All injections were performed approximately 2 h before behavioral testing.

**ODOR DISCRIMINATION FLEXIBILITY TASK**

**BEHAVIORAL ASSAY**

Mice were habituated to reinforcers (sweetened yogurt chips; Bio-Serv, Flemington, NJ, USA) and the test environment (3 min/day) for 7 and 5 days, respectively, preceding shaping trials (Figure 3A). Following habituation, two cups scented individually with 100 μL peanut oil (Amazon, #B00QGWM57M, USA) and 2-phenylethanol (2-PE; Sigma-Aldrich, #77861, USA)
were placed at east and west ends of the test arena (Supplementary Figure 2, courtesy of G.F. League Co., Inc., Greenville, SC, USA), in recessed areas where reinforcers (quartered to reduce satiation) remained out of sight until a nose poke response was made. One reinforcer was available per trial.

Mice were trained 5 days per week in the two-choice operant paradigm wherein one olfactory stimulus was paired with the reinforcer (Figure 3A). Odorants were used at response sites to aid in stimulus discrimination (65) and mask any odor which may be present in reinforcers, which could otherwise bias response learning (66). Reward-paired scent was randomly assigned and counterbalanced across subjects, and target location was randomized between trials to preclude location-based learning. Experimenters were blind to subject genotype throughout behavioral testing and data analysis.

SHAPING TRIALS

Subjects were placed into a holding chamber at the south end of the test arena. To signal a trial, the holding area was briefly (2 s) illuminated from above with a mildly aversive white LED light before the partition was lifted to cue access to the darker test arena, illuminated with red light. The white trial signal light remained on until subjects entered the test area or for 1 min of no entry, after which point subjects were manually directed to the arena from the holding chamber. Upon subject entry, the partition was closed and latency to interact with reward-paired odor location was recorded. Trials began when the subject body crossed into the testing area, and terminated upon reward consumption. All sessions were video-recorded (GoPro Hero6 Black; GoPro Smart Remote; Vanguard ESPOD CX1OS tripod) and analyzed by two experimenters to assess response latency and correctness (97.92% inter-rater agreement; Cohen’s $k = 0.79$).
DRUG ADMINISTRATION

After consistent discriminative choice for the cup paired with reward was established (i.e., a nose poke into the positive predictor cup and no interaction with the negative predictor cup across 8 out of 10 consecutive trials; 12–60 days), subjects were injected subcutaneously as described above. Shaping trials were continued during drug habituation to maintain learned responses, and reversal training began on injection day 6 (Figure 3A).

REVERSAL TRAINING

The reversal paradigm was identical to that of shaping, except the opposite scent predicted reward. Injections were administered daily throughout reversal training. After consistent discriminative choice for the opposite cup was established (using the same criteria for the acquisition phase; 9–35 days), the experiment was terminated and subjects advanced to protein quantification analysis with mass spectrometry. Within-trial response latency was recorded to assess potential locomotor deficits/cannabimimetic effects presenting as slower approach to a reward-predictive cue.

REINFORCER CONSUMPTION TEST

Tat has previously been shown to induce reward deficits and increase sensitivity to reinforcer-induced reward enhancement, contributing to depressive and addictive phenotypes, respectively (67). To measure anhedonic response and assess whether genotype influences reward salience of the reinforcer used in the ODF task, a consumption test and olfactory sensitivity test was conducted with a separate cohort of mice in home cages. After 5 days habituation to reinforcers, subjects were given access to a large amount of reinforcer (1.35 g) for 5 min and total volume consumed was quantified by measuring change in reinforcer weight.
OLFACTORY SENSITIVITY TEST

Olfaction abilities were probed to ensure genotype-dependent differences in acquisition latency were not due to greater sensitivity of one group in detecting reinforcer odor in the ODF task. In this task, a reinforcer was buried in the center of home cages 0.5 cm beneath the bedding surface (68). Subjects were placed inside the south end of the cage, and latency to locate and consume the reinforcer was recorded. Trials terminated upon reinforcer consumption or after 5 min, whichever occurred first.

ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY (UPLC-MS/MS)

Subjects were sacrificed by rapid decapitation following isoflurane-induced anesthesia and brains were collected, dissected, and snap-frozen in liquid nitrogen. Calibration curves were prepared at the following concentrations: 0.028 pmol to 2.8 pmol for N-arachidonoyl ethanolamine (anandamide; AEA), 2.6 pmol to 260 pmol for 2-arachidonoylglycerol (2-AG), 0 and 0.033 nmol to 3.3 nmol for AA along with negative and blank controls. Samples were stored at −80 °C until the day of analysis. The internal standard (ISTD) was added to each calibrator, control, and sample except the blank control at concentrations of 0.28 pmol AEA-d8, 26 pmol 2-AG-d8, 0 and 0.33 nmol AA-d8. The calibrator, control and samples were analyzed as previously described (69). In brief, samples were homogenized in 100 μL ethanol and then 900 μL water was added. Sample cleanup was performed using UCT Clean Up® C18 solid phase extraction column (United Chemical Technologies, Inc., Bristol, PA, USA) conditioned with methanol followed by water. Samples were added and the columns were then washed with deionized water. Lipids were eluted with methanol, evaporated under nitrogen, and reconstituted in mobile phase. A Shimadzu UPLC
system (Kyoto, Japan) attached to a Sciex 6500 QTRAP system with an IonDrive Turbo V source for TurbolonSpray® (Sciex, Ontario, Canada) controlled by Analyst software (Sciex, Ontario, Canada) was used for the analysis of AEA, 2-AG, and AA.

Chromatographic separation of AEA, 2-AG, and AA was performed on a Discovery® HS C18 Column 15 cm × 2.1 mm, 3 μm (Supelco: Bellefonte, PA, USA) kept at 25°C. The mobile phase consisted of A: acetonitrile and B: water with 1 g/L ammonium acetate and 0.1% formic acid. The following gradient was used: 0.0–2.4 min at 40% A, 2.5–6.0 min at 40% A, hold for 2.1 min at 40% A, then 8.1–9 min 100% A, hold at 100% A for 3.1 min and return to 40% A at 12.1 min with a flow rate of 1.0 mL/min. The source temperature was 600°C with ionspray voltage of 5,000 V. The curtain gas and source gases 1 and 2 had flow rates of 30, 60, and 50 mL/min, respectively. The mass spectrometer was operated in multiple reaction monitoring (MRM) positive ionization mode for AEA, 2-AG, and negative ionization mode for AA. The following transition ions (m/z) with their corresponding collection energies (eV) in parentheses were measured as follows: AEA: 348>62 (13) and 348>91 (60); AEA-d8: 356>63 (13); 2-AG: 379>287 (26) and 379>296 (28); 2-AG-d8: 384>287 (26); AA: 303>259 (-25) and 303>59 (-60); AA-d8: 311>267 (-25). The total run time for the analytical method was 14 min. Calibration curves were analyzed with each analytical batch for each analyte. A linear regression of the ratio of the peak area counts of analyte and corresponding deuterated ISTD vs. concentration was used to construct calibration curves.

DATA ANALYSIS

Mean [Ca^{2+}]_i change time course data from in vitro experiments were analyzed using analysis of variance (ANOVA) when appropriate. Violations of compound symmetry in repeated-measures ANOVAs for the within-subjects factors (i.e., comparing time points) were
addressed by using the Greenhouse-Geisser degrees ($p_{GG}$) of freedom correction factor (70). Separate ANOVAs followed by Bonferroni post-hoc analysis were conducted for the final 10 min of the experimental time course to assess differences in sustained excitation between treatment groups.

Behavioral data for the shaping phase are plotted as latency (days) required to meet advancement criteria, and were analyzed as survival curves using the logrank test. Behavioral data for the reversal phase are plotted as latency (days) to meet completion criteria and latency (seconds) to meet criteria within trials, and were analyzed using Cox regression and two-way ANOVAs with genotype [2 levels: Tat(–) mice, Tat(+) mice] and MJN110 treatment (2 levels: vehicle, MJN110 1 mg/kg) as between-subjects factors where appropriate followed by Bonferroni post-hoc tests.

Brain region-specific endocannabinoid levels were analyzed by two-way ANOVAs with genotype [2 levels: Tat(–) mice, Tat(+) mice] and MJN110 treatment (2 levels: vehicle, MJN110 1 mg/kg) as between-subjects factors followed by Bonferroni post-hoc tests and correlated with mean within-trial response latency for the reversal phase.

All data are presented as mean ± SEM. Alpha values of < 0.05 were considered significant for all statistical tests. All experiments and data analyses were carried out by experimenters blind to treatment conditions.
RESULTS

LIVE-CELL FLUORESCENCE IMAGING

GLUTAMATE-INDUCED INTRACELLULAR [Ca^{2+}]_i INCREASE WAS DYSREGULATED BY TAT PRETREATMENT AND DOWNREGULATED BY MJN110 IN A CONCENTRATION-DEPENDENT MANNER

To understand the role of MAGL inhibition and Tat in mediating neurotoxicity after a glutamate challenge, [Ca^{2+}]_i responses of frontal cortex neuron cultures pretreated with Tat (50 nM) and MJN110 (0–1 μM) and then challenged with glutamate (10 μM) during imaging (Figure 1) were investigated. For excitation, various glutamate concentrations were tested (0.1–10 μM) to induce a sustained [Ca^{2+}]_i response for 30 min in frontal cortex neurons (Supplementary Figure 1). A three-way mixed ANOVA was conducted with Tat application [2 levels: control, Tat 50 nM], MJN110 treatment (3 levels: vehicle, 0.5 μM, 1 μM) as between-subjects factors and time as a within-subjects factor. Results demonstrated a significant main effect for time \([F(40, 12, 400) = 61.6, p_{GG} < 0.001]\) and MJN110 \([F(2, 310) = 34.9, p < 0.001]\). Further significant interactions were noted for time x MJN110 \([F(80, 12, 400) = 16.6, p_{GG} < 0.001]\), time x Tat x drug \([F(80, 12, 400) = 4.7, p_{GG} < 0.001]\), and Tat x MJN110 \([F(2, 310) = 7.2, p = 0.001]\) (Figure 1B). A two-way ANOVA with Tat and MJN110 treatments as between-subjects factors was conducted on the last 10 min of the experimental time course and revealed a significant MJN110 effect \([F(2, 310) = 29.0, p < 0.001]\) and Tat x MJN110 interaction \([F(2, 310) = 4.6, p = 0.010]\) with MJN110 significantly downregulating [Ca^{2+}]_i levels in a concentration dependent manner. Only in the presence of Tat, MJN110 0.5 μM elicited a significant attenuation of the glutamate-induced [Ca^{2+}]_i activity.
compared to MJN110-free vehicle application \((p < 0.001)\). MJN110 0.5 μM did not significantly downregulate \([\text{Ca}^{2+}]_i\) levels compared to vehicle for control conditions when Tat was absent (Figure 1C).

**FIGURE 1** Primary frontal cortex neuron cultures (DIV 7-11) were untreated or pre-incubated with different concentrations of MJN110 (0–1 μM) and/or a subthreshold concentration of Tat 50 nM before Ca2+ imaging began (1 h and 30 min prior, respectively). (A) Pseudocolor images of neuronal ratiometric calcium imaging taken 30 min after a glutamate (GLT) 10 μM challenge (except for the control condition) with comparing frontal cortex neurons pre-incubated with vehicle solution or different concentrations of MJN110 (0.5 – 1 μM) and/or a subthreshold concentration of Tat 50 nM. (B) \([\text{Ca}^{2+}]_i\) levels were plotted over a 30 min time period with GLT 10 μM being applied at the 1-min mark (arrow). Application of GLT 10 μM onto neurons caused significant increases in \([\text{Ca}^{2+}]_i\) levels in the presence and absence of Tat and this effect was inhibited with MJN110 pretreatment in a concentration dependent manner. (C) The \([\text{Ca}^{2+}]_i\) levels are summarized for the last 10 min of calcium assessment and indicate that the lower concentration of MJN110 (0.5μM) is more inhibitory in the presence of Tat compared to the control condition. An alpha level of \(p < 0.05\) was considered significant for all statistical tests. \(^{*}p < 0.05\) vs. GLT 10 μM (PRE: Control); \(^{**}p < 0.05\) vs. GLT 10 μM (PRE: Tat 50 nM); \(^{S}p < 0.05\) vs. MJN110 0.5 μM + GLT 10 μM (PRE: Control). GLT, glutamate; PRE, pretreatment.
TAT-INDUCED DYSREGULATION OF [Ca^{2+}]_{i} INCREASE WAS MITIGATED BY PRETREATMENT WITH MJN110 IN A TIME- AND CONCENTRATION-DEPENDENT MANNER

To understand the role of MAGL inhibition in Tat-mediated neurotoxicity, [Ca^{2+}]_{i} responses of frontal cortex neuron cultures to Tat 100 nM when pretreated with vehicle or MJN110 (0.5–1 μM) 30 min or 1-h prior imaging (Figure 2) was investigated. Two-way mixed ANOVAs were conducted with treatment (4 levels: control, Tat 100 nM, MJN110 0.5 μM +Tat, MJN110 1 μM + Tat) as a between-subjects factor and time as a within-subjects factor. When MJN110 was applied to neuron cultures 30 min prior Tat 100 nM, results demonstrated a significant main effect for time \([F(40, 11, 760) = 9.3, p_{GG} < 0.001]\), a main effect of treatment \([F(3, 294) = 10.6, p < 0.001]\), and a time x treatment interaction \([F(120, 11, 760) = 2.4, p = 0.001]\) (Figure 2A). A one-way ANOVA conducted on the last 10 min revealed a significant treatment effect \([F(3, 294) = 5.5, p = 0.001]\), with Tat 100 nM treatment and pretreatment of MJN110 1 μM + Tat showing significantly higher [Ca^{2+}]_{i} levels compared to the control condition \((p = 0.001\) and \(p = 0.036\), respectively; Figure 2A'). The MJN110 0.5 μM + Tat condition was not significantly different from control, nor did it differ from the Tat and MJN110 1 μM + Tat groups; thus indicating 30-min pretreatment with MJN110 prior Tat 100 nM excitation is not sufficient to inhibit [Ca^{2+}]_{i} levels in frontal cortex neuron cultures.

When MJN110 was pretreated 1 h prior Tat 100 nM exposure, a two-way mixed ANOVA demonstrated a significant main effect for time \([F(40, 11, 840) = 6.4, p_{GG} < 0.001]\), a main effect of treatment \([F(3, 296) = 17.0, p < 0.001]\), and a time x treatment interaction \([F(120, 11, 840) = 2.7, p < 0.001]\) (Figure 2B). A one-way ANOVA conducted on the last 10 min of the experimental time course revealed a significant treatment effect \([F(3, 296) = 6.0, p = 0.001]\), with only Tat 100 nM treatment displaying significantly higher [Ca^{2+}]_{i} levels compared to the control condition \((p < 0.001\) and significantly differing from the MJN110 0.5 μM + Tat condition \((p =\)
No other effect was noted to be significant. Thus, results suggest that MJN110 pretreatment for 1 h prior to Tat 100 nM excitation is able to inhibit [Ca\(^{2+}\)]\(i\) activity in frontal cortex neuron cultures.

**FIGURE 2** | Primary frontal cortex neuron cultures (DIV 7-11) were untreated or pre-incubated for (A) 30 min or (B) 1 h with different concentrations of MJN110 before [Ca\(^{2+}\)]\(i\) imaging began. [Ca\(^{2+}\)]\(i\) levels were plotted over a 30-min time period with Tat 100 nM being applied at the 1-min mark (arrow). (A) Pre-incubation of MJN110 for 30 min prior to Tat application was not able to inhibit significant increases in [Ca\(^{2+}\)]\(i\) induced by Tat when observed across a 30-min time period. (A') The [Ca\(^{2+}\)]\(i\) levels are summarized for the last 10 min of calcium assessment and indicate that none of the MJN110 concentrations is able to inhibit Tat-induced increases in [Ca\(^{2+}\)]\(i\) levels. (B) Pre-incubation of MJN110 for 1 h prior to Tat application inhibited Tat-associated [Ca\(^{2+}\)]\(i\) upregulation over a 30-min time period. (B') The [Ca\(^{2+}\)]\(i\) levels are summarized for the last 10 min of calcium assessment and indicate that MJN110 0.5 μM was able to significantly inhibit Tat-induced [Ca\(^{2+}\)]\(i\) increases. An alpha level of \(p < 0.05\) was considered significant for all statistical tests. *\(p < 0.05\) vs. Control; #\(p < 0.05\) vs. Tat 100 nM.
IMMUNOCYTOCHEMISTRY

DENDRITIC BRANCHING COMPLEXITY WAS INCREASED IN TAT-EXPOSED FRONTAL CORTEX NEURONS TREATED WITH MJN110

Soma area (μm²), maximum process length (μm), and distance from soma with maximal branching (defined by radial distance from the center of the soma with maximum number of intersections) were analyzed to assess changes to neuronal morphology driven by Tat (100 nM) and/or MJN110 (1 μM, Table 1). A two-way ANOVA with Tat and MJN110 treatment as between-subjects factors for soma area displayed no significant effect and/or interaction for Tat or MJN110 treatment. Maximum process length was also not significantly altered by MJN110, but trended toward decreased length in neurons treated with Tat ($p = 0.070$, Table 1). Distance from soma with maximal branching was significantly increased with MJN110 treatment and displayed a significant Tat x MJN110 treatment interaction such that Tat-untreated neurons showed no significant branch pattern differences with MJN110 treatment ($p = 0.810$), but Tat-treated neurons displayed significant increases in branching complexity with MJN110 treatment ($p = 0.002$, Table 1).

| Measure                              | Tat            | Vehicle      | MJN110 (1 μM) | Tat effect | MJN110 effect | Tat x MJN110 |
|--------------------------------------|----------------|--------------|---------------|------------|---------------|--------------|
|                                      | Mean ± SEM     | Mean ± SEM   | $F_{1,32}$    | $p$        | $F_{1,32}$    | $p$          |
| Soma area (μm²)                      | Control        | 174.6 ± 20.37| 174.5 ± 13.86| <1.0       | <1.0          | <1.0         |
|                                      | Tat            | 179.8 ± 41.10| 184.7 ± 21.00| 0.77       | 0.93          | 0.93         |
| Maximum process length (μm)          | Control        | 67.8 ± 2.55  | 72.3 ± 5.01   | 3.5        | 1.8           | 1.0          |
|                                      | Tat            | 59.0 ± 4.72  | 65.6 ± 3.74   | 0.07       | 0.19          | 0.81         |
| Distance from soma with maximal      | Control        | 26.1 ± 2.32  | 28.9 ± 2.32   | <1.0       | 11.6          | -0.01        |
| branching (μm)                       | Tat            | 19.4 ± 1.94  | 31.7 ± 2.21   | 0.38       | 4.6           | 0.04         |

*Sholl analysis of neuronal morphology in frontal cortex neuron cultures in vehicle- or MJN110-treated control or Tat-treated neurons expressed as the mean ± SEM. The parameters measured by Sholl analysis are indicated in the first column. One-way ANOVAs for each dependent measure were conducted with Tat and MJN110 treatment as between-subjects factors. F-values and p-values are presented from ANOVA results. Bolded values denote significant differences at $α = 0.05$; mean ± SEM, $n = 9$ cells per group.
ODOR DISCRIMINATION FLEXIBILITY TASK

RATE OF SHAPING ACQUISITION WAS FASTER IN TAT(+) SUBJECTS

Behavioral acquisition in the shaping phase of the ODF task was analyzed to assess whether genotype affected the rate of task learning. Shaping acquisition was significantly faster in Tat(+) relative to Tat(−) subjects [Figure 3B; $X^2(1,N=23) = 6.422, p = 0.011$].

FASTER REVERSAL ACQUISITION IN TAT(+) SUBJECTS WAS SLOWED TO RATES COMPARABLE TO TAT(−) CONTROLS WITH MJN110 TREATMENT

Reversal acquisition latency was separately assessed to determine the effects of genotype and MJN110 treatment specifically on cognitive flexibility. While the effect of genotype demonstrated significance in omnibus tests of behavioral acquisition in the reversal phase [$X^2(3,N=21) = 7.983, p = 0.046$], it was found to be statistically insignificant when treatment and its interaction with genotype were taken into account (Table 2). Specifically, within Tat(+) subjects, MJN110 treatment significantly increased the number of trials required to acquire the

**FIGURE 3** | (A) Behavioral timeline schematic for the two-choice Odor Discrimination Flexibility (ODF) task. (B) Tat(+) subjects acquired the shaping task significantly faster than Tat(−) controls. (B') MJN110-treated Tat(+) subjects acquired the reversal task significantly slower than vehicle-treated Tat(+) subjects. An alpha level of $p < 0.05$ was considered significant for all statistical tests. *$p < 0.05$ vs. Tat(−); #$p < 0.05$ vs. Tat(+)/vehicle.
reversal learning task (Figure 3B); 22.00 ± 2.32 vs. 15.00 ± 1.84 for MJN110- and saline-treated subjects, respectively; \( p = 0.048 \) presenting as latencies more similar to Tat(–) subjects.

| Variables in the equation | B    | SE   | Wald | df | Sig.  | Exp(B) | 95% CI for Exp(B) |
|---------------------------|------|------|------|----|-------|--------|------------------|
| Genotype                 | −0.624 | 0.598 | 1.098 | 1 | 0.287 | 0.536 | 0.166 1.731 |
| Treatment                | 0.428 | 0.612 | 0.489 | 1 | 0.485 | 1.634 | 0.462 5.092 |
| Genotype/Treatment       | −1.328 | 0.434 | 1.959 | 1 | 0.162 | 0.265 | 0.041 1.702 |

\( ^b \)Cox regression with genotype and treatment as factors. While omnibus tests found a significant effect of genotype in reversal learning, this effect loses significance when treatment and its interaction with Tat are factored into the model.

**NEITHER GENOTYPE NOR MJN110 TREATMENT SIGNIFICANTLY AFFECTED WITHIN-TRIAL RESPONSE LATENCY**

Response latency within trials was also assessed to determine whether genotype or drug treatment affected the speed with which subjects approached the reward-predictive cue. No significant effects of Tat or MJN110 on within-trial response latency were observed (Figure 4A; \( p = 0.337 \) and 0.368, respectively), indicating locomotor deficits/cannabinimimetic effects were not likely factors driving observed differences.

**FIGURE 4** (A) No significant differences were observed between groups in response latency within reversal trials. (B) No significant differences in volume of reinforcer consumed were observed between genotypes. (C) No significant differences were observed between Tat(+) and Tat(–) subjects in latency to locate a hidden reinforcer. An alpha level of \( p < 0.05 \) was considered significant for all statistical tests. RF, reinforcer.
**TAT EXPRESSION DID NOT INFLUENCE REINFORCER CONSUMPTION VOLUME**

No significant differences were observed between Tat(−) and Tat(+) subjects in total volume consumed in the test session (Figure 4B), indicating the observed effect was not dependent upon appetite differences between groups.

**TAT EXPRESSION DID NOT INFLUENCE OLFACTORY SENSITIVITY**

While previous work has demonstrated increased odor detection thresholds in HIV-positive relative to HIV-negative individuals (71), no differences in latency were observed between genotypes (Figure 4C), indicating the effect captured in the ODF task was not driven by genotype-associated differential sensitivity to odor.

**UPLC-MS/MS**

**2-AG AND AEA WERE DIFFERENTIALLY EXPRESSED ACROSS EXAMINED BRAIN REGIONS BETWEEN TAT AND MJN110 CONDITIONS**

2-AG, AEA, and AA levels were quantified in the prefrontal cortex (PFC), hippocampus, and striatum to characterize the effects of genotype and MJN110 treatment on brain region-specific endocannabinoid levels. In vehicle-treated subjects, 2-AG levels across brain regions were not significantly affected by Tat (Figures 5A–A”; PFC $p = 0.501$, hippocampus $p = 0.063$, and striatum $p = 0.155$). However, MJN110 treatment significantly upregulated 2-AG in the PFC [Figure 5A; $F_{(1, 18)} = 4.8$, $p = 0.042$] and striatum [Figure 5A”; $F_{(1, 18)} = 34.1$, $p < 0.0001$]. While Tat(+) subjects had significantly lower PFC AEA levels relative to Tat(−) controls [$F_{(1, 18)} = 11.0$, $p = 0.004$], MJN110 significantly upregulated AEA in this region [Figure 5B; $F_{(1, 18)} = 8.1$, $p = 0.011$]. Neither hippocampal nor striatal AEA levels were significantly altered by MJN110 or Tat (Figures 5B’,B”, respectively). No significant Tat- or MJN110-associated differences in AA levels were observed in any brain region assessed (Figures 5C–C”), though
Tat(+) subjects trended toward lower hippocampal levels across treatments (Figure 5C'; \( p = 0.067 \)).

**PFC AA AND STRIATAL AEA LEVELS POSITIVELY CORRELATED WITH WITHIN-TRIAL RESPONSE LATENCY IN TAT(+) AND MJN110-TREATED SUBJECTS, RESPECTIVELY**

While neither genotype nor MJN110 treatment significantly affected PFC AA levels (\( p = 0.418 \) and \( p = 0.104 \), respectively), these measures were found to be positively correlated with response latency within behavior trials in Tat(+) subjects (\( R^2 = 0.55, p = 0.014 \)). A significant positive relationship was also found between striatal AEA levels and within-trial response latency across groups (\( R^2 = 0.232, p = 0.031 \)). This effect

FIGURE 5 | (A) MJN110 treatment significantly increased PFC 2-AG levels across genotypes. (A’) Neither Tat nor MJN110 significantly affected hippocampal 2-AG levels. (A”) MJN110 significantly increased striatal 2-AG levels across genotypes. (B) Tat(+) subjects across treatment groups had significantly lower PFC AEA levels relative to Tat(−) controls. MJN110 significantly increased PFC AEA in Tat(+) subjects. No significant differences in hippocampal (B’) or striatal AEA (B”) were observed between groups. No significant differences in PFC (C), hippocampal (C’), or striatal AA (C”) were observed between groups. An alpha level of \( p < 0.05 \) was considered significant for all statistical tests. *\( p < 0.05 \) vs. vehicle treatment; **\( p < 0.0001 \) vs. vehicle treatment; #\( p < 0.01 \) vs. Tat(−) subjects. 

21
appears to be driven by MJN110, as drug-treated subjects displayed a stronger relationship than
vehicle-treated controls (MJN110 $R^2 = 0.40, p = 0.050$; vehicle $R^2 = 0.26, p = 0.136$).
DISCUSSION

MJN110 treatment restored intracellular \([\text{Ca}^{2+}]_i\) response and dendritic branching complexity in Tat-treated neurons to that of vehicle-treated controls \textit{in vitro}, and shifted reversal task acquisition latency among Tat(+) subjects to within the statistical range of Tat(-) controls \textit{in vivo}. Given that the behavioral effect corresponded with significant Tat-induced and MJN110-induced increases in hippocampal, prefrontal cortex, and striatal 2-AG levels, the observed latency shift could be linked to treatment-dependent alteration of perceived reward salience.

Tat has been shown to induce neurotoxicity and synaptic damage across murine models of HIV, presenting as N-methyl-D-aspartate (NMDA) receptor phosphorylation, cytokine secretion, expression of apoptotic proteins, reduction of neurite length, and reduced appearance of puncta along neuronal processes (57, 72–75). Increasing 2-AG and AEA have previously been found to rescue effects of Tat in PFC neurons presenting as downregulation of high intracellular calcium levels and increased neuronal survival (20); further, 2-AG has a larger therapeutic window relative to AEA due to its higher physiological expression (76). Both 2-AG and MAGL are implicated in immune activation response control in macrophages and microglia, where 2-AG prevents proinflammatory cytokine production (77) and downregulates hippocampal inflammation-induced cyclooxygenase (COX)-2 expression in response to excitotoxic stimuli (78). MJN110-induced reduction of Tat-driven excitability is likely mediated by inhibitory effects of CB1R agonism \textit{in vitro} as well as interactions with eicosanoid signaling pathways \textit{in vivo} (79), though a CB1R knockout mouse model or co-administration of a CB1R antagonist such as rimonabant would be required to specifically delineate this potential mechanism.
While MJN110 and similar drugs have shown therapeutic potential in models of inflammation-associated neural dysfunction, motivation regulation, stress, and neuropathic pain, beneficial aspects of these treatments may not generalize across test conditions. Elevation of 2-AG may regulate neural activity in subjects susceptible to excitotoxicity, but in a normal physiological context, the upregulation may result paradoxically in proinflammatory effects due to 2-AG hydrolysis into AA. AA metabolizes into other proinflammatory prostaglandins and eicosanoids reported previously to be increased in women living with HIV. An interaction might exist between Tat(−) and Tat(+) subjects such that MJN110 treatment may shift activity of Tat(+) subjects closer to the level of Tat(−) untreated controls. MJN110 may have no additional beneficial effect in physiological systems wherein inhibitory correction is not needed. Alternative strategies may thus target upstream diacylglycerol lipase, responsible for biosynthesis of 2-AG. As MJN110 appears to drive different patterns of behavioral and neuronal activity and structure across physiological and pathological conditions, it could be explored whether depletion of 2-AG upstream might have greater neuroprotective potential as proinflammatory metabolites are further reduced and potential adverse effects of excessive 2-AG upregulation are functionally precluded.

The finding that MJN110 (1 mg/kg) significantly upregulated AEA levels in the PFC of Tat(+) mice warrants further exploration. FAAH inhibition has shown to have brain region-dependent effects on 2-AG levels, but the reverse effect for AEA with MAGL inhibition is less commonly found. While earlier-generation MAGL inhibitors such as JZL184 have some known cross-reactivity with FAAH, more selective MAGL inhibitors including MJN110 or KML29 show negligible cross-reactivity with FAAH and do not elevate AEA levels in the whole brain. Similarly, we have not seen any AEA elevation in control,
Tat(−) mice following repeated treatment with MJN110 at 1 mg/kg. It is likely Tat expression alone modifies endocannabinoid system function in such a way that MAGL blockade results in AEA elevation not observed in control animals, and the mechanism remains to be elucidated. It has been shown previously that Tat reduces the potency of 2-AG-induced inhibition on excitation (30).

HIV-1 has been shown to exert damage to dopaminergic cells and cause synaptic connectivity loss in dopaminergic projection pathways (91), presenting frequently in infected individuals as apathy and motivation dysregulation (92, 93). These behavioral sequelae of HAND are accompanied by increased markers of inflammation in the striatum (94). HIV-1 infection and substance abuse disorders are frequently comorbid (95, 96), and previous work has shown that neurons in regions implicated in reward seeking, such as the medial PFC, are hyperexcitable in the presence of HIV, particularly in models of salient reward self-administration (97, 98). As Tat binds and produces conformational changes to dopamine transporters (99, 100), rewarding effects of reinforcers are also influenced by direct Tat-induced inhibition of dopamine uptake in the striatum (101, 102). Specifically, Tat has been demonstrated to inhibit dopamine transporter (DAT) reuptake function by interacting (i.e., forming hydrogen bonds) with the DAT residues Tyr88 and His547 (103–106). Further, the resulting dopaminergic alterations can drive inflammation and immune dysfunction in PWH (107, 108) and increase susceptibility of these individuals to behavioral dysregulation presenting as greater addiction severity and HAND (109). Given the highly significant effect of MJN110 treatment on striatal 2-AG levels observed presently, subsequent investigations will shift focus to the effect of Tat and MJN110 on reward-seeking behavior as a proxy for motivation.
To better elucidate the effect of MJN110 on potential Tat-induced addiction-like behaviors (110), a progressive fixed ratio reinforcement schedule will be employed in an operant-conditioning task to assess reward-related motivation differences between genotypes and treatment groups. If data are consistent with Kesby et al. (67) and the effect of Tat is altered by MJN110 treatment, it is likely that the most influenced behavioral effect of the drug relies upon its action in cortico- and mesolimbic circuitry.
CONCLUSION

As efforts continue to address shortcomings of currently available therapeutics in HIV-1 treatment, the present study aimed to characterize a potentially viable neuroprotective drug which has been shown to attenuate inflammatory responses across numerous models of CNS insult. Analyzing MAGL inhibition effects on Tat-induced behavioral, neuronal, and endocannabinoid level changes served as a proxy for understanding functional outcomes of chronic endocannabinoid signaling modulation, and whether targeting 2-AG at the stage of hydrolysis may be restorative in models of HAND. While the mechanistic actions and biological outcomes of novel cannabinoid drugs continue to be investigated, characterization of these compounds in disease states (particularly those which currently remain only partially suppressed) serves to broaden our understanding of their utility across models of inflammatory nervous system insult.
REFERENCES

1. UNAIDS. Latest Global and Regional Statistics on the Status of the AIDS Epidemic [Fact sheet]. (2021). Available online at: https://www.unaids.org/en/resources/documents/2021/UNAIDS_FactSheet

2. Ellis RJ, Rosarto D, Clifford DB, MacArthur JC, Simpson D, Alexander T, et al. continued high prevalence and adverse clinical impact of human immunodeficiency virus associated sensory neuropathy in the era of combination antiretroviral therapy. *Arch Neurol.* (2010) 67:552. 10.1001/archneurol.2010.76

3. Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. *J Neurovirol.* (2014) 20:39–53. 10.1007/s13365-013-0227-1

4. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. *Nat Rev Neurosci.* (2007) 8:33–44. 10.1038/nrn2040

5. Alakkas A, Ellis RJ, Watson CW, Umlauf A, Heaton RK, Letendre S, et al. White matter damage, neuroinflammation, and neuronal integrity in HAND. *J Neurovirol.* (2019) 25:32–41. 10.1007/s13365-018-0682-9

6. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. *J Neurovirol.* (2000) 6:145–55. 10.3109/13550280009013158

7. Mediouni S, Jablonski J, Paris J, Clementz C, Thenin-Houssier S, McLaughlin J, et al. Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice. *Curr HIV Res.* (2015) 13:64–79. 10.2174/1570162X13666150121111548

8. Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). *Curr HIV AIDS Rep.* (2015) 12:16–24. 10.1007/s11904-014-0255-3

9. Henderson LJ, Johnson TP, Smith BR, Reoma LB, Santamaria UA, Bachani M, et al. Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. *AIDS.* (2019) 33:S145–57. 10.1097/QAD.0000000000002268

10. Nath A, Steiner J. Synaptodendritic injury with HIV-Tat protein: What is the therapeutic target? *Exp Neurol.* (2014) 251:112–4. 10.1016/j.expneurol.2013.11.004

11. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. *Behav Brain Res.* (2012) 229:48–56. 10.1016/j.bbr.2011.12.019
12. Bertrand SJ, Aksenova MV, Mactutus CF, Booze RM. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. *Exp Neurol.* (2013) 248:228–35. 10.1016/j.expneurol.2013.06.020

13. Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. *Biol Psychiatry.* (2013) 73:443–53. 10.1016/j.biopsych.2012.09.026

14. Marks WD, Paris JJ, Barbour AJ, Moon J, Carpenter VJ, Melane VD, et al. HIV-1 Tat and morphine differentially disrupt pyramidal cell structure and function and spatial learning in hippocampal area CA1: continuous versus interrupted morphine exposure. *Eneuro.* (2021) 8:ENEURO.0547-20. 10.1523/ENEURO.0547-20.2021

15. Hauser KF, Knapp PE. Interactions of HIV and drugs of abuse. *Int Rev Neurobiol.* (2014) 118:231–313. 10.1016/b978-0-12-801284-0.00009-9

16. Ozturk T, Kollhoff A, Anderson AM, Howell JC, Loring DW, Waldrop-Valverde D, et al. Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. *Sci Rep.* (2019) 9:1–10. 10.1038/s41598-019-45418-2

17. Hauser KF, Fitting S, Dever SM, Podhaizer EM, Knapp PE. Opiate Drug Use and the Pathophysiology of NeuroAIDS. *Curr HIV Res.* (2012) 10:435–52. 10.2174/157016212802138779

18. Shin AH, Thayer SA. Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. *Mol Cell Neurosci.* (2013) 54:22–9. 10.1016/j.mcn.2012.12.005

19. Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI, et al. Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na+ influx, mitochondrial instability, and Ca2+ overload. *J Neurosci.* (2014) 34:12850–64. 10.1523/JNEUROSCI.5351-13.2014

20. Xu C, Hermes DJ, Nwanguma B, Jacobs IR, Mackie K, Mukhopadhyay S, et al. Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. *Mol Cell Neurosci.* (2017) 83:92–102. 10.1016/j.mcn.2017.07.003

21. Uhelski ML, Khasabova IA, Simone DA. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. *J Neurophysiol.* (2015) 113:1501–10. 10.1152/jn.00692.2014

22. Parker LA, Limebeer CL, Rock EM, Sticht MA, Ward J, Turvey G, et al. A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models. *Psychopharmacology (Berl).* (2016) 233:2265–75. 10.1007/s00213-016-4277-y
23. Wang Y, Zhang X. FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression. *Behav Brain Res.* (2017) 324:138–45. 10.1016/j.bbr.2017.01.054

24. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. *Br J Pharmacol.* (2014) 171:1392–407. 10.1111/bph.12298

25. Ignatowska-Jankowska BM, Wilkerson JL, Mustafa M, Abdullah R, Niphakis MJ, Wiley JL, et al. Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice. *J Pharmacol Exp Ther.* (2015) 353:424–32. 10.1124/jpet.114.222315

26. Pertwee RG. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. *Proc Nutr Soc.* (2014) 73:96–105. 10.1017/S0029665113003649

27. Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. *Neurotherapeutics.* (2015) 12:692–8. 10.1007/s13311-015-0374-6

28. Howlett AC. Cannabinoid receptor signaling. *Cannabinoids.* (2005) 53–79. 10.1007/3-540-26573-2_2

29. Compagnucci C, Di Siena S, Bustamante MB, Di Giacomo D, Di Tommaso M, Maccarrone M, et al. Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells. *PLoS ONE.* (2013) 8:e54271. 10.1371/journal.pone.0054271

30. Wu MM, Thayer SA. HIV Tat protein selectively impairs CB1 receptor-mediated presynaptic inhibition at excitatory but not inhibitory synapses. *Eneuro.* (2020) 7:ENEURO.0119–0120. 10.1523/ENEURO.0119-20.2020

31. Li X, Han D, Tian Z, Gao B, Fan M, Li C, et al. Activation of cannabinoid receptor type II by AM1241 ameliorates myocardial fibrosis via Nrf2-mediated inhibition of TGF-β1/Smad3 pathway in myocardial infarction mice. *Cell Physiol Biochem.* (2016) 39:1521–36. 10.1159/000447855

32. Hermes DJ, Xu C, Poklis JL, Niphakis MJ, Cravatt BF, Mackie K, et al. Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. *Neuropharmacology.* (2018) 141:55–65. 10.1016/j.neuropharm.2018.08.013

33. Wu MM, Zhang X, Asher MJ, Thayer SA. Druggable Targets of the endocannabinoid system: implications for the treatment of HIV-associated neurocognitive disorder. *Brain Res.* (2019) 1724:146467. 10.1016/j.brainres.2019.146467

34. Yadav-Samudrala BJ, Fitting S. Mini-review: The Therapeutic Role of Cannabinoids in Neurohiv. *Neurosci Lett.* (2021) 750:135717. 10.1016/j.neulet.2021.135717
35. Guha D, Wagner MCE, Ayyavoo V. Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. *J Neuroinflammation.* (2018) 15:126. 10.1186/s12974-018-1160-2

36. McLaurin KA, Cook AK, Li H, League AF, Mactutus CF, Booze RM. Synaptic connectivity in medium spiny neurons of the nucleus accumbens: a sex-dependent mechanism underlying apathy in the HIV-1 transgenic rat. *Front Behav Neurosci.* (2018) 12:285. 10.3389/fnbeh.2018.00285

37. Makhathini KB, Abboussi O, Mabandla MV, Daniels WMU. The effects of repetitive stress on tat protein-induced pro-inflammatory cytokine release and steroid receptor expression in the hippocampus of rats. *Metab Brain Dis.* (2018) 33:1743–53. 10.1007/s11011-018-0283-6

38. Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. *Philos Trans R Soc B Biol Sci.* (2012) 367:3286–99. 10.1098/rstb.2011.0392

39. Yi Z, Xie L, Zhou C, Yuan H, Ouyang S, Fang Z, et al. P2Y 12 receptor upregulation in satellite glial cells is involved in neuropathic pain induced by HIV glycoprotein 120 and 2’, 3’-dideoxycytidine. *Purinergic Signal.* (2018) 14:47–58. 10.1007/s11302-017-9594-z

40. Bagdas D, Paris JJ, Carper M, Wodarski R, Rice ASC, Knapp PE, et al. Conditional expression of HIV-1 tat in the mouse alters the onset and progression of tonic, inflammatory and neuropathic hypersensitivity in a sex-dependent manner. *Eur J Pain.* (2020) 24:1609–23. 10.1002/ejp.1618

41. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? *Nat Rev Drug Discov.* (2008) 7:438–55. 10.1038/nrd2553

42. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. *Chem Rev.* (2008) 108:1687–707. 10.1021/cr0782067

43. Lichtman AH, Blankman JL, Cravatt BF. Endocannabinoid overload. *Mol Pharmacol.* (2010) 78:993–5. 10.1124/mol.110.069427

44. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. *Curr Opin Invest Drugs.* (2010) 11:51–62.

45. Dinh TP, Carpenter D.l, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci USA.* (2002) 99:10819–24. 10.1073/pnas.152334899

46. Blankman JL, Simon GM, Cravatt BF. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol. *Chemistry and Biology.* (2007) 14:1347–56. 10.1016/j.chembiol.2007.11.006

47. Rahmani MR, Shamsizadeh A, Mohgadam-Ahmedi A, Bazmandegan G, Allahtavakoli M. JZL184, as a monoacylglycerol lipase inhibitor, down-regulates inflammation in a
cannabinoid pathway dependent manner. Biomed Pharmacother. (2018) 103:1720–6. 10.1016/j.biopharm.2018.05.001

48. Sakin YS, Dogrul A, Ilkaya F, Seyrek M, Ulas UH, Gulsen M, et al. The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents. Neurogastroenterol Motility. (2015) 27:936–44. 10.1111/nmo.12563

49. Muldoon PP, Akinola LS, Schlosburg JE, Lichtman AH, Sim-Selley LJ, Mahadevan A, et al. Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice. Neuropharmacology. (2020) 176:108170. 10.1016/j.neuropharm.2020.108170

50. Zhang X, Thayer SA. Monoacylglycerol lipase inhibitor JZL184 prevents HIV-1 gp120-induced synapse loss by altering endocannabinoid signaling. Neuropharmacology. (2018) 128:269–81. 10.1016/j.neuropharm.2017.10.023

51. Ren SY, Wang ZZ, Zhang Y, Chen NH. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors. Acta Pharmacol Sin. (2020) 41:1263–71. 10.1038/s41401-020-0385-7

52. Choi SH, Arai AL, Mou Y, Kang B, Yen CCC, Hallenbeck J, et al. Neuroprotective effects of MAGL (Monoacylglycerol Lipase) inhibitors in experimental ischemic stroke. Stroke. (2018) 49:718–26. 10.1161/STROKEAHA.117.019664

53. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, et al. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 tat transgenic mice. Glia. (2008) 56:1414–27. 10.1002/glia.20708

54. Fellows LK. Ventromedial frontal cortex mediates affective shifting in humans: evidence from a reversal learning paradigm. Brain. (2003) 126:1830–7. 10.1093/brain/awg180

55. O'Doherty JP. Reward representations and reward-related learning in the human brain: insights from neuroimaging. Curr Opin Neurobiol. (2004) 14:769–76. 10.1016/j.conb.2004.10.016

56. Ridderinkhof KR. The Role of the Medial Frontal Cortex in Cognitive Control. Science. (2004) 306:443–7. 10.1126/science.1100301

57. Kruman II, Nath A, Mattson MP. HIV-1 protein tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol. (1998) 154:276–88. 10.1006/exnr.1998.6958

58. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, et al. Morphine Exacerbates HIV-1 Tat-Induced Cytokine Production in Astrocytes through Convergent Effects on [Ca2+]i, NF-κB Trafficking and Transcription. PLoS ONE. (2008) 3:e4093. 10.1371/journal.pone.0004093
59. El-Hage N, Podhaizer EM, Sturgill J, Hauser KF. Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and Morphine. *Immunol Invest.* (2011) 40:498–522. 10.3109/08820139.2011.561904

60. Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, et al. Human immunodeficiency Virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and vmax. *J Neurosci.* (2010) 30:14153–64. 10.1523/JNEUROSCI.1042-10.2010

61. Niphakis MJ, Cognetta AB, Chang JW, Buczynski MW, Parsons LH, Byrne F, et al. Evaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors. *ACS Chem Neurosci.* (2013) 4:1322–32. 10.1021/cn400116z

62. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca$^{2+}$ indicators with greatly improved fluorescence properties. *J Biol Chem.* (1985) 260:3440–50. 10.1016/S0021-9258(19)83641-4

63. Kumamoto N, Gu Y, Wang J, Janoschka S, Takemaru KI, Levine J, et al. A role for primary cilia in glutamatergic synaptic integration of adult-born neurons. *Nat Neurosci.* (2012) 15:399–405. 10.1038/nn.3042

64. Chauhan A, Turchan J, Pocernich C, Bruce-Keller A, Roth SD, Butterfield A, et al. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. *J Biol Chem.* (2003) 278:13512–9. 10.1074/jbc.M209381200

65. Liu G, Patel JM, Tepe B, McClard CK, Swanson J, Quast KB, et al. An objective and reproducible test of olfactory learning and discrimination in mice. *J Vis Exp.* (2018) 133:e57142. 10.3791/57142

66. Rokni D, Hemmelder V, Kapoor V, Murthy VN. An olfactory cocktail party: figure-ground segregation of odorants in rodents. *Nat Neurosci.* (2014) 17:1225–32. 10.1038/nn.3775

67. Kesby JP, Markou A, Semenova S. The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice. *Neuropharmacology.* (2016) 109:205–15. 10.1016/j.neuropharm.2016.06.011

68. Yang M, Crawley JN. Simple behavioral assessment of mouse olfaction. *Curr Prot Neurosci.* (2009) 48:Unit 8.24. 10.1002/0471142301.ns0824s48

69. Dempsey SK, Gesseck AM, Ahmad A, Daneva Z, Ritter JK, Poklis JL. Formation of HETE-EAs and dihydroxy derivatives in mouse kidney tissue and analysis by high-performance liquid chromatography tandem mass spectrometry. *J Chromatogr B.* (2019) 1126–1127:121748. 10.1016/j.jchromb.2019.121748

70. Greenhouse SW, Geisser S. On methods in the analysis of profile data. *Psychometrika.* (1959) 24:95–112. 10.1007/BF02289823 [CrossRef] [Google Scholar]
71. Mueller C, Temmel AFP, Quint C, Rieger A, Hummel T. Olfactory Function in HIV-positive Subjects. *Acta Otolaryngol.* (2002) 122:67–71. 10.1080/00016480252775760

72. Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schettini G. HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat *Neurons.* (2001) 288:301–8. 10.1006/bbrc.2001.5743

73. Hategan A, Bianchet MA, Steiner J, Karnaukhova E, Masliah E, Fields A, et al. HIV Tat protein and amyloid-β peptide form multifibrillar structures that cause neurotoxicity. *Nat Struct Mol Biol.* (2017) 24:379–86. 10.1038/nsmb.3379

74. Nass SR, Hahn YK, Mclane VD, Varshneya NB, Damaj MI, Knapp PE, et al. Chronic HIV-1 Tat exposure alters anterior cingulate cortico-basal ganglia-thalamocortical synaptic circuitry, associated behavioral control, and immune regulation in male mice. *Brain Behav Immun Health.* (2020) 5:100077. 10.1016/j.bbih.2020.100077

75. Tang X, Lu H, Ramratnam B. Neurotoxicity of HIV-1 Tat is attributed to its penetrating property. *Sci Rep.* (2020) 10:14002. 10.1038/s41598-020-70950-x

76. Gil-Ordóñez A, Martín-Fontecha M, Ortega-Gutiérrez S, López-Rodríguez ML. Monoacylglycerol lipase (MAGL) as a promising therapeutic target. *Biochem Pharmacol.* (2018) 157:18–32. 10.1016/j.bcp.2018.07.036

77. Krishnan G, Chatterjee N. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. *Glia.* (2012) 60:1629–45. 10.1002/glia.22380

78. Zhang J, Chen C. Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation. *J Biol Chem.* (2008) 283:22601–11. 10.1074/jbc.M800524200

79. Kohnz RA, Nomura DK. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. *Chem Soc Rev.* (2014) 43:6859–69. 10.1039/C4CS00047A

80. Hermes DJ, Yadav-Samudrala BJ, Xu C, Paniccia JE, Meeker RB, Armstrong ML, et al. GPR18 Drives FAAH Inhibition-induced Neuroprotection Against HIV-1 Tat-induced Neurodegeneration. *Exp Neurol.* (2021) 341:113699. 10.1016/j.expneurol.2021.113699

81. Feja M, Leigh MPK, Baindur AN, McGraw JJ, Wakabayashi KT, Cravatt BF, et al. The novel MAGL inhibitor MJN110 enhances responding to reward-predictive incentive cues by activation of CB1 receptors. *Neuropsychopharmacology.* (2020) 162:107814. 10.1016/j.neuropharm.2019.107814

82. Grabner GF, Zimmermann R, Schäch R, Taschner U. Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. *Pharmacol Ther.* (2017) 175:35–46. 10.1016/j.pharmthera.2017.02.033
83. Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. *Journal of Pharmacol Exp Ther.* (2016) 357:145–56. 10.1124/jpet.115.229971

84. Grabner GF, Eichmann TO, Wagner B, Gao Y, Farzi A, Taschler U, et al. Deletion of monoglyceride lipase in astrocytes attenuates lipopolysaccharide-induced neuroinflammation. *J Biol Chem.* (2016) 291:913–23. 10.1074/jbc.m115.683615

85. Weinberg A, Huo Y, Kacanek D, Patel K, Watts DH, Wara D, et al. Brief report. *J Acquir Immune Defic Syndr.* (2019) 82:181–7. 10.1097/QAI.0000000000002111

86. Ueda N, Tsuboi K, Uyama T, Ohnishi T. Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. *Biofactors.* (2011) 37:1–7. 10.1002/biof.131

87. Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allara M, et al. The inhibition of 2-arachidonoylglycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. *Cell Death Dis.* (2013) 4:e862. 10.1038/cddis.2013.387

88. Wilkerson JL, Donvito G, Grim TW, Abdullah RA, Ogasawara D, Cravatt BF, et al. Investigation of diacylglycerol lipase alpha inhibition in the mouse lipopolysaccharide inflammatory pain model. *J Pharmacol Exp Ther.* (2017) 363:394–401. 10.1124/jpet.117.243808

89. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? *Trends Pharmacol Sci.* (2008) 29:229–33. 10.1016/j.tips.2008.03.001

90. Chang JW, Niphakis MJ, Lum KM, Cognetta AB, Wang C, Matthews ML, et al. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. *Chem Biol.* (2012) 19:579–88. 10.1016/j.chembiol.2012.03.009

91. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National NeuroAIDS tissue consortium brain gene array: two types of HIV-associated neurocognitive impairment. *PLoS ONE.* (2012) 7:e46178. 10.1371/journal.pone.0046178

92. Bryant VE, Whitehead NE, Burrell LE, Dotson VM, Cook RL, Kathryn Devlin K, et al. Depression and apathy among people living with HIV: implications for treatment of HIV associated neurocognitive disorders. *AIDS Behav.* (2015) 19:1430–7. 10.1007/s10461-014-0970-1

93. Nickoloff-Bybel EA, Calderon TM, Gaskill PJ, Berman JW. HIV Neuropathogenesis in the presence of a disrupted dopamine system. *J Neuroimmune Pharmacol.* (2020) 15:729–42. 10.1007/s11481-020-09927-6

94. Bade AN, Gorantla S, Dash PK, Makarov E, Sajja BR, Poluektova LY, et al. Manganese-enhanced magnetic resonance imaging reflects brain pathology during progressive HIV-1
infection of humanized mice. *Mol Neurobiol.* (2016) 53:3286–97. 10.1007/s12035-015-9258-3

95. Cook JA, Burke-Miller JK, Steigman PJ, Schwartz RM, Hessol NA, Milam J, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. *AIDS Behav.* (2018) 22:3141–54. 10.1007/s10461-018-2051-3

96. Illenberger JM, Harrod SB, Mactutus CF, Mclaurin KA, Kallianpur A, Booze RM. HIV infection and neurocognitive disorders in the context of chronic drug abuse: evidence for divergent findings dependent upon prior drug history. *J Neuroimmune Pharmacol.* (2020) 15:715–28. 10.1007/s11481-020-09928-5

97. Ferris MJ, Mactutus CF, Booze RM. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. *Neurosci Biobehav Rev.* (2008) 32:883–909. 10.1016/j.neubiorev.2008.01.004

98. Wayman WN, Chen L, Hu XT, Napier TC. HIV-1 Transgenic rat prefrontal cortex hyper-excitability is enhanced by cocaine self-administration. *Neuropsychopharmacology.* (2016) 41:1965–73. 10.1038/npp.2015.366

99. Zhu J, Ananthan S, Mactutus CF, Booze RM. Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. *Synapse.* (2011) 65:1251–4. 10.1002/syn.20949

100. Yuan Y, Huang X, Midde NM, Quizon PM, Sun WL, Zhu J, et al. Molecular Mechanism of HIV-1 Tat Interacting with Human Dopamine Transporter. *ACS Chem Neurosci.* (2015) 6:658–65. 10.1021/acscemneuro.5b00001

101. Paris JJ, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP. Effects of conditional central expression of HIV-1 Tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice. *Neuropsychopharmacology.* (2017) 39:380–8. 10.1038/npp.2013.201

102. Javadi-Paydar M, Roscoe RF, Denton AR, Mactutus CF, Booze RM. HIV-1 and cocaine disrupt dopamine reuptake and medium spiny neurons in female rat striatum. *PLoS ONE.* (2017) 12:e0188404. 10.1371/journal.pone.0188404

103. Quizon PM, Yuan Y, Zhu Y, Zhou Y, Strauss MJ, Sun W-L, et al. Mutations of human dopamine transporter at tyrosine88, aspartic Acid206, and histidine547 influence basal and HIV-1 tat-inhibited dopamine transport. *J Neuroimmune Pharmacol.* (2021). 10.1007/s11481-021-09984-5

104. Midde NM, Yuan Y, Quizon PM, Sun WL, Huang X, Zhan CG, et al. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-Induced Inhibition of dopamine transport. *Neuroimmune Pharmacol.* (2015) 10:122–35. 10.1007/s11481-015-9583-3
105. Quizon PM, Sun WL, Yuan Y, Midde NM, Zhan CG, Zhu J. (2016). Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport. *Sci. Rep.* (2016) 6:39048. 10.1038/srep39048

106. Sun WL, Quizon PM, Yuan Y, Strauss MJ, McCain R, Zhan CG, et al. Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport. *Sci Rep.* (2019) 9:3843. 10.1038/s41598-019-39872-1

107. Matt SM, Gaskill PJ. Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. *Brain Res.* (2019) 1723:146398–146398. 10.1016/j.brainres.2019.146398

108. Nolan RA, Muir R, Runner K, Haddad EK, Gaskill PJ. Role of macrophage dopamine receptors in mediating cytokine production: implications for neuroinflammation in the context of Hiv-associated neurocognitive disorders. *J Neuroimmune Pharmacol.* (2019) 14:134–56. 10.1007/s11481-018-9825-2

109. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment. *Nat Rev Neurol.* (2016) 12:234–48. 10.1038/nrneurol.2016.27

110. Panee J, Pang X, Munsaka S, Berry MJ, Chang L. Independent and Co-morbid HIV infection and meth use disorders on oxidative stress markers in the cerebrospinal fluid and depressive symptoms. *J Neuroimmune Pharmacol.* (2015) 10:111–21. 10.1007/s11481-014-9581-x